Best Papers. F. Fusco

Size: px
Start display at page:

Download "Best Papers. F. Fusco"

Transcription

1 Best Papers UROLOGY F. Fusco

2 Best papers RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND

3 This cohort reflects the current clinical situation of EBRT in the era of IMRT Aims To compare outcomes, including mortality, of RP and EBRT for localized PC. Methods We retrospectively analyzed 891 patients with ct1-4n0m0 PC who underwent either RP (n = 569) or EBRT (n = 322) with curative intent at our single institution between 2005 and Of the EBRT patients, 302 (93.8%) underwent intensity-modulated radiotherapy. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). Related to these, other-cause mortality (OCM) was also calculated. Biochemical recurrence-free survival was assessed as a secondary endpoint. Median follow-up durations were 53 and 45 months, in the RP and EBRT groups, respectively.

4 Overall survival ALL RISKS

5 Overall survival LOW RISK

6 Overall survival INTERMEDIATE RISK

7 Overall survival HIGH RISK

8 Cancer specific survival ALL GROUPS

9 Cancer specific survival LOW RISK There was no death from PCa in men with low D Amico risk

10 Cancer specific survival INTERMEDIATE RISK There was one death in men with intermediate D Amico risks in the EBRT group

11 Cancer specific survival HIGH RISK In high-risk patients, significantly more patients died from PCa in the EBRT group than the RP group

12 Predictors of cancer specific survival RP might be the better choice, especially for high-risk patients

13 Aims to describe changes in treatment patterns for clinical T3 prostate cancer (PCa) from 1998 to 2012, specifically investigating what factors influence receipt of prostatectomy or radiation Methods Using the Surveillance, Epidemiology, and End Results database, we studied 11,604 men with clinical T3N0M0 PCa from 1998 to 2012, with treatment categorized as radiation, radical prostatectomy (RP), or no curative therapy. Michelle D. Nezolosky., et al., Urologic Oncology, 2015

14 Treatment trends for overall cohort 55.8% 44.4% 31.7% 12.5% 38.4% 17.2%, Significant increase in the use of RP for clinical T3 PCa and a significant decrease in the use of radiation such that Rates of prostatectomy increased significantly from 1998 to 2012, radiation decreased significantly,and receipt of no treatment also decreased ( all P < 0.001). In 2012, the use of prostatectomy exceeded the use of radiation. Michelle D. Nezolosky., et al., Urologic Oncology, 2015

15 Treatment trends for ct3a and ct3b These trends were similar for clinical T3a and T3b. Rates of prostatectomy surpassed radiation by 2008 in clinical T3a,reaching 49.8%vs.37.1%,respectively,in 2012(P=0.002), and were statistically similar to radiation in 2012 for clinical T3b,reaching 41.6%vs.42.1%. Michelle D. Nezolosky., et al., Urologic Oncology, 2015

16 Predictors of RP use Multivariable logistic regression analysis demonstrated that patients were more likely to receive RP if: Younger, Lower initial PSA, Biopsy Gleason scores of 5 to 7 vs. Gleason scores of 8 to 10 disease, Lower country-education level (all P < 0.04) Michelle D. Nezolosky., et al., Urologic Oncology, 2015

17 Aims The relationship between the number of removed lymph nodes (RLNs) and cancer-specific mortality (CSM) was tested in patients with LNI. Methods We examined data of 315 pn1 PCa patients treated with radical prostatectomy (RP) and anatomically eplnd between 2000 and 2012 at one tertiary care centre. All patients received adjuvant hormonal therapy with or without adjuvant radiotherapy (art).

18 Cancer specific survival Kaplan-Meier survival estimates based on multivariable analysis, depicting cancerspecific survival rate in 315 pn1 prostate cancer patients treated with surgery and adjuvant treatment. Patients were stratified according to (a) the total number of lymph nodes removed

19 Cancer specific survival Kaplan-Meier survival estimates based on multivariable analysis, depicting cancer-specific survival rate in 315 pn1 prostate cancer patients treated with surgery and adjuvant treatment. Patients were stratified according to (b) the most informative cut-off for the association between the number of nodes removed and cancer-specific survival.

20 Cancer specific mortality - predictors An eplnd should be considered in all patients with a significant preoperative risk of harbouring an LNI (INTERMEDIATE/HIGH RISK PATIENTS)

21 Objective: To examine long-term outcomes of salvage LND in patients with nodal recurrent PCa documented by 11C-choline positron emission tomography/computed tomography (PET/CT) scan. Design, setting, and participants: Overall, 59 patients affected by biochemical recurrence (BCR) with 11C-choline PET/CT scan with pathologic activity treated between 2002 and 2008 were included. Intervention: Pelvic and/or retroperitoneal salvage LND.

22 Outcome measurements Biochemical response (BR) was defined as prostate-specific antigen (PSA) <0.2 ng/ml at 40 d after surgery. biochemical recurrence (BCR) for those who achieved BR was defined as a PSA >0.2 ng/ml. Clinical recurrence (CR) was defined as a positive PET/CT scan after salvage LND in the presence of a rising PSA. Kaplan-Meier curves assessed time to BCR, CR, and cancerspecific mortality (CSM).

23 Results Median follow-up after salvage LND was 81.1 mo. Overall, 35 patients (59.3%) achieved BR The 8-yr BCR-free survival rate in patients with complete BR was 23%. Overall, the 8-yr CR- and CSM-free survival rates were 38% and 81%, respectively.

24 Models predicting clinical recurrence after salvage lymph node dissection In multivariable analyses evaluating preoperative variables, PSA at salvage LND represented the only predictor of CR ( p = 0.03).

25 Models predicting clinical recurrence after salvage lymph node dissection When postoperative variables were considered, BR and the presence of retroperitoneal lymph node metastases were significantly associated with the risk of CR (all p 0.04).

26 Conclusions: Salvage LND may represent a therapeutic option for patients with BCR after RP and nodal pathologic uptake at 11C-choline PET/CT scan. Although most patients progressed to BCR after salvage LND, roughly 40% of them experienced CR-free survival. Ideal candidates for such an approach are patients with a small volume of nodal recurrence limited to the pelvic area.

27 Aims To assess rates of treatment-related complications after radical prostatectomy or radiotherapy monotherapy Methods On the basis of a population-based study of men undergoing surgery or radiotherapy for prostate cancer in Ontario between 2002 and 2009, we undertook a propensity score matched analysis including age, comorbidity, and year of treatment to assess treatment-related complication end points. These included: hospital admission; urologic, rectal, or anal procedures; open surgeries; and secondary malignancies. Wallis C.J.D., et al., UROLOGY, 2015

28

29 From the original cohort of 32,465 patients, 15,870 (48.9%) had surgery and 16,595 (51.1%) had radiation. Propensity score matching produced 8797 pairs (17,594 patients). Using propensity score analysis and direct matching techniques, we showed that patients who underwent radiotherapy for prostate cancer had an increased risk of long-term complications across all 5 measures compared with patients who had surgery when accounting for age, comorbidity, and year of treatment. When the analysis was restricted to only patients receiving full 3D treatment preparation for radiotherapy, the results were similar Wallis C.J.D., et al., UROLOGY, 2015

30 Conclusions 1.Better oncological outcomes with RP in high risk patients 2.Increasing use of RP over RT 3.Potential therapeutic role of elnd 4.Lower long term complications rate with RP

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo

L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo Paolo Gontero Division of Urology Città della Salute e della Scienza

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

Correspondence should be addressed to Taha Numan Yıkılmaz;

Correspondence should be addressed to Taha Numan Yıkılmaz; Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score

More information

Debate: Whole pelvic RT for high risk prostate cancer??

Debate: Whole pelvic RT for high risk prostate cancer?? Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,

More information

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Overview of Radiotherapy for Clinically Localized Prostate Cancer Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive

More information

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients

More information

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy

More information

Date Modified: May 29, Clinical Quality Measures for PQRS

Date Modified: May 29, Clinical Quality Measures for PQRS Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3

More information

How to deal with patients who fail intracavitary treatment

How to deal with patients who fail intracavitary treatment How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned

More information

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate

More information

Providing Treatment Information for Prostate Cancer Patients

Providing Treatment Information for Prostate Cancer Patients Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact

More information

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,

More information

Prostate Cancer Local or distant recurrence?

Prostate Cancer Local or distant recurrence? Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Personalized Therapy for Prostate Cancer due to Genetic Testings

Personalized Therapy for Prostate Cancer due to Genetic Testings Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center

More information

10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018

10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

IN RADIOTERAPIA BEST PAPERS. Direttore Unità Operativa Complessa Radioterapia Oncologica

IN RADIOTERAPIA BEST PAPERS. Direttore Unità Operativa Complessa Radioterapia Oncologica IN RADIOTERAPIA BEST PAPERS 2014 FILIPPO ALONGI Direttore Unità Operativa Complessa Radioterapia Oncologica PROSTATE RT: WHERE WE ARE GOING? RT has evolved from radium(1911) to high Technology and high

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

Alberto Briganti, M.D., PhD

Alberto Briganti, M.D., PhD Alberto Briganti, M.D., PhD Professore Orinario di Urologia IRCCS San Raffaele Divisione di Oncologia / Unità di Urologia Urological Research Institute (URI) Università Vita-Salute San Raffaele, Milano

More information

Prostate MRI: Who needs it?

Prostate MRI: Who needs it? Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center

More information

Date Modified: March 31, Clinical Quality Measures for PQRS

Date Modified: March 31, Clinical Quality Measures for PQRS Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process

More information

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy

More information

SIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico

SIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases

More information

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,

More information

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on

More information

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools

More information

Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience.

Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Elisabetta Ponti MD, Gianluca Ingrosso MD, Alessandra Carosi PhD, Luana

More information

Newer Aspects of Prostate Cancer Underwriting

Newer Aspects of Prostate Cancer Underwriting Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions

More information

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7  Abstract: ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated

More information

Prostate Cancer UK s Best Practice Pathway

Prostate Cancer UK s Best Practice Pathway Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS

More information

Predictive factors of late biochemical recurrence after radical prostatectomy

Predictive factors of late biochemical recurrence after radical prostatectomy JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original

More information

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

State-of-the-art: vision on the future. Urology

State-of-the-art: vision on the future. Urology State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures

More information

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer

More information

Key words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality

Key words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

University of Groningen. Morphological aspects of recurrent prostate cancer Rybalov, Maxim

University of Groningen. Morphological aspects of recurrent prostate cancer Rybalov, Maxim University of Groningen Morphological aspects of recurrent prostate cancer Rybalov, Maxim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.

More information

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence

More information

3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?

3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014? 3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor

More information

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael

More information

When radical prostatectomy is not enough: The evolving role of postoperative

When radical prostatectomy is not enough: The evolving role of postoperative When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer

More information

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer Beauval et al. BMC Urology (2016) 16:26 DOI 10.1186/s12894-016-0146-6 RESEARCH ARTICLE Open Access Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk

More information

Does Imaging of Advanced PC change a suggested treatment?

Does Imaging of Advanced PC change a suggested treatment? Does Imaging of Advanced PC change a suggested treatment? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials and conflict

More information

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.

More information

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology

More information

PET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark

PET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark PET/CT imaging and RIT of prostate cancer Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark Prostate cancer Prostate cancer is the most common malignancy in men Imaging

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason

More information

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher

More information

Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy

Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with

More information

Focal Therapy is a Fool s Paradise : The whole prostate must be treated!

Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy

More information

Clinical Case Conference

Clinical Case Conference Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

GUIDELINEs ON PROSTATE CANCER

GUIDELINEs ON PROSTATE CANCER GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent

More information

High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera

High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993

More information

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging Whole Body MRI Prostate Cancer recurrence, progression and restaging Dr. Nina Tunariu Consultant Radiology Drug Development Unit and Prostate Targeted Therapies Group 12-13 Janeiro 2018 Evolving Treatment

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

Ga 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney

Ga 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney Ga 68 -HBED- PSMA A/ProfLouise Emmett St Vincent s Hospital Sydney Glu-NH-CO-NH-Lys-(Ahx)- [68Ga(HBED-CC)] Prostate specific membrane antigen 35 pub-med publications 15 clinical 3 retrospective larger

More information

Trimodality Therapy for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,

More information

Radioligand imaging & treatment of prostate cancer

Radioligand imaging & treatment of prostate cancer Radioligand imaging & treatment of prostate cancer Christiaan Schiepers, MD, PhD University of California Los Angeles CANM-CAMRT JOINT ANNUAL CONFERENCE MARCH 22-24, 2018 VANCOUVER, B.C. I do not have

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience

Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience european urology 51 (2007) 121 129 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution

More information

Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration

Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,

More information

Prostate Cancer and Prostatic Disease (2014), Macmillan Publishers Limited All rights reserved /14

Prostate Cancer and Prostatic Disease (2014), Macmillan Publishers Limited All rights reserved /14 Prostate Cancer and Prostatic Disease (2014), 1 7 2014 Macmillan Publishers Limited All rights reserved 1365-7852/14 www.nature.com/pcan ORIGINAL ARTICLE Predicting prostate cancer-specific outcome after

More information

PSMA PET in patients with prostate cancer

PSMA PET in patients with prostate cancer PSMA PET in patients with prostate cancer Thomas Hope, MD Assistant Professor of Radiology, UCSF Abdominal Imaging and Nuclear Medicine Co-director, PET/MRI Chief of MRI, San Francisco VA Medical Center

More information

Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy

Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy european urology 55 (2009) 404 411 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy

More information

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Lymphadenectomy in RCC: Yes, No, Clinical Trial? Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University

More information

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend

More information

Review of Polish and international guidelines on hormonal therapy in localized prostate cancer

Review of Polish and international guidelines on hormonal therapy in localized prostate cancer Review article NOWOTWORY Journal of Oncology 2016, volume 66, number 5, 403 407 DOI: 10.5603/NJO.2016.0071 Polskie Towarzystwo Onkologiczne ISSN 0029 540X www.nowotwory.edu.pl Review of Polish and international

More information

Accepted Manuscript. S (18) /j.adro Reference: ADRO 244. To appear in: Advances in Radiation Oncology

Accepted Manuscript. S (18) /j.adro Reference: ADRO 244. To appear in: Advances in Radiation Oncology Accepted Manuscript Percutaneous image guided nodal biopsy after C-11 Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications B.T. Welch, A.T.

More information

CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy

CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Original research CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Michel Zimmermann, MD; 1 Guila Delouya, MD, MSc; 1,2 Abdullah M. Alenizi, MD;

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,

More information

Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes

Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes UROLCHI World J Urol DOI 10.1007/s00345-015-1515-6 ORIGINAL ARTICLE Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes Rodrigo A.

More information

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Jason D. Wright, MD, Yongemei Huang, MD/PhD, William M. Burke, MD, et al. Journal Club March 16, 2016 Blaine Campbell-PGY2 Objective

More information

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN

More information